Based on the biomarkers currently being studied for clinical practice [27,28,29,30], pre-clinical biomarkers (1) Aβ, (2) tau, (3) inflammation, (4) oxidative stress, (5) neurodegeneration, as well as (6) cognitive impairment were selected to investigate the pre-clinical anti-AD evidence of sulforaphane, and its effectiveness and plausible mechanisms. Here, MAPT is linked to Cognitive impairment.